Integrating Molecular Profiling of Liquid Biopsy Samples with a Calculator Algorithm To Detect High-risk Prostate Cancer

European Urology

Volumn 70, Issue 5, 2016, Pages 749-750

  Gardiner, Robert A ^a,b,c   Mainwaring, Paul ^d   Lavin, Martin F ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d ICON Cancer Care   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; CALCULATOR; CANCER PREVENTION; CLINICAL PRACTICE; COHORT ANALYSIS; DIGITAL RECTAL EXAMINATION; EARLY CANCER; EDITORIAL; EMERGENCY HEALTH SERVICE; FAMILY HISTORY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; MULTICENTER STUDY (TOPIC); MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE FLUID; RISK FACTOR; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; URINE SAMPLING; VALIDATION STUDY; ALGORITHM; BIOPSY; LIQUID BIOPSY; PROSTATE TUMOR; RISK ASSESSMENT;

ALGORITHMS; BIOPSY; HUMANS; LIQUID BIOPSY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84973623373     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.05.012     Document Type: Editorial

References (8)

1. [1] Van Neste, L., Hendriks, R.J., Dijkstra, S., et al. Detection of high-grade prostate cancer using a urinary molecular-based biomarker risk score. Eur Urol 70 (2016), 740–748.
2. [2] Leyten, G.H., Hessels, D., Smit, F.P., et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res 21 (2015), 3061–3070.
3. [3] Groskopf, J., Aubin, S.M., Deras, I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006), 1089–1095.
4. [4] Leyten, G.H., Hessels, D., Jannink, S.A., et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 65 (2014), 534–542.
5. [5] Tomlins, S.A., Day, J.R., Lonigro, R.J., et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 70 (2016), 45–53.
6. [6] Donovan, M.J., M Noerholm, M., Bentink, S., et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostat Dis 18 (2015), 370–375.
7. [7] Hendriks, R.J., Dijkstra, S., Jannink, S.A., et al. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin Chem Lab Med 54 (2016), 483–492.
8. [8] Leyten, G.H., Wierenga, E.A., Sedelaar, J.P., et al. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci 14 (2013), 11347–11355.